Am­gen steers PC­SK9 block­buster hope­ful through an­oth­er promis­ing PhI­II, but the crit­i­cal test is loom­ing

Am­gen took an­oth­er step down a long path aimed at out­lin­ing the health ad­van­tages of­fered by its PC­SK9 drug Repatha. In a Phase III study, re­searchers for the com­pa­ny said that the drug hit the pri­ma­ry end­point, sig­nif­i­cant­ly re­duc­ing the need for a pro­ce­dure known as aphere­sis, which is used to counter high LDL lev­els in cer­tain at-risk pa­tients.

The drug, al­ready ap­proved to con­trol cho­les­terol, al­so met sec­ondary end­points on the per­cent change from base­line to week 4 in LDL-C, non-high-den­si­ty lipopro­tein cho­les­terol (non-HDL-C) and to­tal cho­les­terol: HDL-C ra­tio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.